All In Biotech

Drug Trial Radar · NCT02345161

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (With an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler With Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily Via a Reservoir Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Jul 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,811 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,811

Actual

Start

Jan 23, 2015

Primary completion

Apr 1, 2016

Study completion Apr 7, 2016

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IIIa, randomised, double-blind, double-dummy, parallel group multicenter study evaluating once daily FF/UMEC/VI (100 microgram \[mcg\]/62.5 mcg/25 mcg) inhalation powder versus twice daily budesonide/formoterol (400 mcg/12 mcg). The primary purpose of this study is to demonstrate improvements in lung function and health status for subjects treated with FF/UMEC/VI compared with budesonide/formoterol for 24 weeks. Once-daily 'closed' triple therapy of a Inhaled Corticosteroid/ Long-acting Muscarinic Receptor Antagonists/ Long Acting Beta-Agonist (ICS/LAMA/LABA) combination FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg) in a single device is being developed with the aim of providing a new treatment option for the management of advanced (GOLD Group D) COPD which will reduce the exacerbation frequency, allow for a reduced burden of polypharmacy, convenience, and increase the potential for improvement in lung function, Health Related Quality of Life (HRQoL) and symptom control over established dual/monotherapies. Subjects meeting all inclusion/exclusion criteria and who have successfully completed all protocol procedures at the Screening Visit will enter the two-week run-in period. Following the run-in period, eligible subjects will be randomised (1:1) to one of the following double-blind treatment groups: FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg via the ELLIPTA™ dry powder inhaler (DPI) once daily in the morning and placebo via reservoir inhaler twice daily OR Budesonide/formoterol 400 mcg/12 mcg via reservoir inhaler twice daily and placebo via the ELLIPTA DPI once daily in the morning. The target enrollment is 1800 randomised subjects at approximately 200 study centers globally. The total duration of subject participation will be approximately 27 weeks, consisting of a 2-week run-in period, 24-week treatment period and a 1-week follow-up period. Subjects will run-in on their existing COPD medications for 2 weeks and in addition will be provided with short acting albuterol/salbutamol to be used on an as-needed basis (rescue medication) throughout the study. Subjects will discontinue all existing COPD medications during the randomised treatment period but may continue their study supplied rescue albuterol/salbutamol. A sub-set of approximately 400 subjects will remain on blinded study treatment for up to a total of 52 weeks to provide additional long term safety data. ELLIPTA and NUBULES are a trade marks of the GlaxoSmithKline Group of Companies. Other company or product names mentioned herein may be the property of their respective owners

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Triple FF/UMEC/VIDrug

    The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.

  • Placebo to match FF/UMEC/VIDrug

    The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).

  • Budesonide/FormoterolDrug

    The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.

  • Placebo to match Budesonide/Formoterol combinationDrug

    The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.

  • Albuterol/salbutamolDrug

    Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24Time frame: Baseline to Week 24
  2. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 52Time frame: Baseline to Week 52
  3. Change From Baseline in St George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease (COPD; SGRQ) Total Score for COPD Participants at Week 24Time frame: Baseline to Week 24
  4. Change From Baseline in St George's Respiratory Questionnaire-COPD; SGRQ Total Score for COPD Participants at Week 52Time frame: Baseline to Week 52

Locations

159 sites in 15 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Dimitrovgrad, Bulgaria

  • GSK Investigational Site

    Lovech, Bulgaria

  • GSK Investigational Site

    Pleven, Bulgaria

  • GSK Investigational Site

    Plovdiv, Bulgaria

  • GSK Investigational Site

    Rousse, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Vidin, Bulgaria

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Wuxi, China

  • GSK Investigational Site

    Guangzhou, Guangdong, China

  • GSK Investigational Site

    Haikou, Hainan, China

  • GSK Investigational Site

    Shenyang, Liaoning, China

  • GSK Investigational Site

    Shenyang, Liaoning, China

  • GSK Investigational Site

    Hangzhou, Zhejiang, China

  • GSK Investigational Site

    Boskovice, Czechia

  • GSK Investigational Site

    Brandýs nad Labem, Czechia

  • GSK Investigational Site

    Cvikov, Czechia

  • GSK Investigational Site

    Karlovy Vary, Czechia

  • GSK Investigational Site

    Kralupy nad Vltavou, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Rokycany, Czechia

  • GSK Investigational Site

    Tábor, Czechia

  • GSK Investigational Site

    Teplice, Czechia

  • GSK Investigational Site

    Haapsalu, Estonia

  • GSK Investigational Site

    Kohtla-Järve, Estonia

  • GSK Investigational Site

    Pärnu, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tartu, Estonia

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Hamburg, Germany

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.